Intercept Pharmaceuticals' stock trading was halted due to the FDA Advisory Committee review of Obeticholic Acid. The outcome of the review could have a significant impact on the stock price, either positively or negatively, depending on the FDA's decision. As the review is ongoing, the short-term impact is neutral.